Lower prevalence of drug resistance mutations at first-line virological failure to first-line therapy with atripla vs. tenofovir + emtricitabine/lamivudine + efavirenz administered on a multiple tablet therapy
Conclusions:Compared to patients receiving the STR-Atripla, those receiving the same components individually in a non-STR regimen have a statistically significantly increased risk of selecting for DRMs associated with their drugs on failure. (Source: AIDS)
Source: AIDS - October 31, 2014 Category: Infectious Diseases Tags: Clinical Science Source Type: research
Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate Single-Tablet Regimen: A Review of Its Use in HIV Infection
Abstract
The nucleos(t)ide reverse transcriptase inhibitors, emtricitabine and tenofovir disoproxil fumarate (tenofovir DF), and the non-nucleoside reverse transcriptase inhibitor, rilpivirine, are now available as a fixed-dose single-tablet regimen (emtricitabine/rilpivirine/tenofovir DF; Complera®, Eviplera®) for the treatment of adults infected with HIV-1. In treatment-naïve adults, once-daily emtricitabine/rilpivirine/tenofovir DF was noninferior to once-daily emtricitabine/efavirenz/tenofovir DF with regard to establishing virological suppression over 96 weeks of therapy in a randomized, open-lab...
Source: Drugs - October 29, 2014 Category: Drugs & Pharmacology Source Type: research
Stribild ® : a guide to its use in HIV-1 infection in adults in the EU
Abstract
The oral fixed-dose elvitegravir/cobicistat/emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF) single tablet (Stribild®) is an approved antiretroviral therapy (ART) for the treatment of ART-naive adult patients with HIV-1 infection or those infected with HIV-1 without known mutations associated with resistance to any of the three antiretroviral agents in Stribild®. The low pill burden and convenient administration regimen mean Stribild® is likely to enhance adherence to treatment. In clinical trials, Stribild® treatment for up to 144 weeks provided durable suppression of plasma HIV-1 ...
Source: Drugs and Therapy Perspectives - October 13, 2014 Category: Drugs & Pharmacology Source Type: research
Stribild®: a guide to its use in HIV-1 infection in adults in the EU
Abstract
The oral fixed-dose elvitegravir/cobicistat/emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF) single tablet (Stribild®) is an approved antiretroviral therapy (ART) for the treatment of ART-naive adult patients with HIV-1 infection or those infected with HIV-1 without known mutations associated with resistance to any of the three antiretroviral agents in Stribild®. The low pill burden and convenient administration regimen mean Stribild® is likely to enhance adherence to treatment. In clinical trials, Stribild® treatment for up to 144 weeks provided durable suppression of plasma HIV-1 RN...
Source: Drugs and Therapy Perspectives - September 26, 2014 Category: Drugs & Pharmacology Source Type: research
Rilpivirine Versus Efavirenz with Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-Naïve HIV-1–Infected Patients with HIV-1 RNA ≤100,000 Copies/mL: Week 96 Pooled ECHO/THRIVE Subanalysis
AIDS Patient Care and STDs , Vol. 0, No. 0. (Source: AIDS Patient Care and STDs)
Source: AIDS Patient Care and STDs - March 25, 2014 Category: Infectious Diseases Tags: article Source Type: research
Rilpivirine, emtricitabine and tenofovir resistance in HIV-1-infected rilpivirine-naive patients failing antiretroviral therapy
Conclusions
In patients failing an NRTI plus NNRTI-based regimen, to know the feasibility of a switch to rilpivirine/emtricitabine/tenofovir disoproxil fumarate, reliable resistance information should be available at the time of use of concurrent NNRTI therapy. (Source: Journal of Antimicrobial Chemotherapy)
Source: Journal of Antimicrobial Chemotherapy - March 17, 2014 Category: Microbiology Authors: Lambert-Niclot, S., Charpentier, C., Storto, A., Fofana, D., Soulie, C., Fourati, S., Wirden, M., Morand-Joubert, L., Masquelier, B., Flandre, P., Calvez, V., Descamps, D., Marcelin, A. G. Tags: Original research Source Type: research
In vitro assessment of antiretroviral drugs demonstrates potential for ototoxicity.
Abstract
Several studies have reported an increased incidence of auditory dysfunction among HIV/AIDS patients. We used auditory HEI-OC1 cells in cell viability, flow cytometry and caspases 3/7-activation studies to investigate the potential ototoxicity of fourteen HIV antiretroviral agents: Abacavir, AZT, Delavirdine, Didenosine, Efavirenz, Emtricitabine, Indinavir, Lamivudine, Nefinavir, Nevirapine, Tenofovir, Ritonavir, Stavudine and Zalcitabine, as well as combinations of these agents as used in the common anti-HIV cocktails Atripla™, Combivir™, Epzicom™, Trizivir™, and Truvada™. Our results s...
Source: Hearing Research - January 31, 2014 Category: Audiology Authors: Thein P, Kalinec GM, Park C, Kalinec F Tags: Hear Res Source Type: research
Stribild, a Single Tablet Regimen for the Treatment of HIV Disease
Conclusion
Stribild had a favorable safety profile in the two recently published randomized, double-blind, phase 3 clinical trials. With the approval of Stribild, clinicians now have more flexibility in prescribing single-tablet regimens for patients. (Source: Combination Products in Therapy)
Source: Combination Products in Therapy - December 1, 2013 Category: Drugs & Pharmacology Source Type: research
Stribild, a Single Tablet Regimen for the Treatment of HIV Disease
ConclusionStribild had a favorable safety profile in the two recently published randomized, double-blind, phase 3 clinical trials. With the approval of Stribild, clinicians now have more flexibility in prescribing single-tablet regimens for patients. (Source: Combination Products in Therapy)
Source: Combination Products in Therapy - December 1, 2013 Category: Drugs & Pharmacology Source Type: research
Dead-end complexes contribute to the synergistic inhibition of HIV-1 RT by the combination of rilpivirine, emtricitabine, and tenofovir.
In this study, two-drug combinations of TFV+FTC, RPV+TFV, and RPV+FTC inhibited HIV replication in cell culture with strong synergy and no evidence of antagonism. The triple drug combination of RPV+FTC+TFV displayed moderate synergy comparable to efavirenz (EFV)+FTC+TFV. The formation of dead-end complexes (DEC) of HIV-1 reverse transcriptase (RT), NRTI chain-terminated primer/template, and the next complementary nucleotide or NNRTIs was studied using gel mobility shift assays. DEC formation was seen with TFV-terminated DNA primer/template, HIV-1 RT, and FTC-triphosphate (TP) in addition to the natural nucleotide dCTP, thu...
Source: Antiviral Research - November 28, 2013 Category: Virology Authors: Kulkarni R, Feng JY, Miller MD, White KL Tags: Antiviral Res Source Type: research
The holý trinity: the acyclic nucleoside phosphonates.
Abstract
The Holý Trinity was named after Dr Antonín Holý (the Holý Trinity being an Unesco recognized monument in Olomouc, Czech Republic), who together with Dr John C. Martin (Gilead Sciences) and myself pioneered a new class of antiviral agents, the acyclic nucleoside phosphonates. These compounds have revolutionized the antiviral drug field with several drugs that have been approved for the treatment of various DNA virus infections (cidofovir), hepatitis B (adefovir), and AIDS (HIV infection; tenofovir). The latter is also available as its oral prodrug, tenofovir disoproxil fumarate, for the treatm...
Source: Advances in Pharmacology - July 29, 2013 Category: Drugs & Pharmacology Authors: De Clercq E Tags: Adv Pharmacol Source Type: research
Combination therapy Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate Associated with Hepatic Failure.
Abstract
A single pill daily fixed dose combination of Efavirenz, Emtricitabine, and Tenofovir Disoproxil Fumarate (EFV/FTC/TDF) provides a potent and convenient treatment option for HIV/AIDS. The components have been shown to be well tolerated and are effective in randomized controlled trials. A literature search revealed no case of hepatic failure reported with this drug combination. We here in describe the 1st case of acute hepatic failure developing after 3 months of treatment with EFV/FTC/TDF in a 41 year old African American male without pre-existing liver disease or risk factors.
PMID: 23373...
Source: Current Drug Safety - February 1, 2013 Category: Drugs & Pharmacology Authors: Qayyum S Tags: Curr Drug Saf Source Type: research
Efavirenz/emtricitabine/tenofovir disoproxil fumarate: Psychosis due to efavirenz?: case report
(Source: Reactions)
Source: Reactions - January 12, 2013 Category: Drugs & Pharmacology Tags: Short communication Source Type: research
Atripla issues of efficacy resistance and adherence
Rebick G, Walmsley SL (Source: Virus Adaptation and Treatment)
Source: Virus Adaptation and Treatment - September 5, 2012 Category: Virology Source Type: research
Discontinuation of Atripla as first-line therapy in HIV-1 infected individuals
Discussion: One-fifth of all individuals commencing Atripla will need to switch therapy, often for adverse events. The commonest reason for switch in our cohort was CNS toxicity, which although it may develop shortly after initiation may persist, ultimately leading to discontinuation of Atripla months or years later. (Source: AIDS)
Source: AIDS - July 17, 2012 Category: Infectious Diseases Tags: Clinical Science: Concise Communications Source Type: research
